Drug Type Stem cell therapy |
Synonyms ORCA-Q, OrcaGraft, OrcaQ |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 2 | United States | 16 Aug 2022 | |
Acute Myeloid Leukemia | Phase 2 | United States | 16 Aug 2022 | |
Blast Phase Chronic Granulocytic Leukemia | Phase 2 | United States | 16 Aug 2022 | |
Chronic phase chronic myeloid leukemia | Phase 2 | United States | 16 Aug 2022 | |
Mixed phenotype acute leukemia | Phase 2 | United States | 16 Aug 2022 | |
Refractory Acute Undifferentiated Leukemia | Phase 2 | United States | 16 Aug 2022 | |
Multiple Sclerosis, Primary Progressive | Phase 1 | - | 01 Mar 2025 | |
Multiple Sclerosis, Secondary Progressive | Phase 1 | - | 01 Mar 2025 | |
High Risk Myelodysplastic Syndrome | Phase 1 | United States | - | |
Multiple Sclerosis | IND Application | United States | - |
NCT03802695 (ASH2024) Manual | Phase 1 | 14 | vtbsbxtwyp(nvwjtsusfp) = oxzmeqyluy nrolutifbl (ymmclqbwcf ) View more | Positive | 07 Dec 2024 | ||
NCT03802695 (ASH2023) Manual | Phase 1 | 33 | jasoyrcqzr(jluquomrkm) = sawdfkzoju bezfhqijkt (sppqvghvre ) View more | Positive | 11 Dec 2023 | ||
Not Applicable | - | edsbgjnjnf(ktatgwnduy) = awocirstvk yivtdtzisq (fdvnnwtxxk ) View more | - | 01 Sep 2023 | |||
Phase 1 | 21 | Orca-Q cell therapy | btxdrbduqw(eispprcdfw) = trmmeakzdc cxdajaukvv (xhovewkwlg ) View more | Positive | 01 Feb 2023 |